Business Context and Reporting Period
This Form 8-K is filed by Pluristem Therapeutics Inc. (Pluri Inc.) on December 10, 2015, reporting an event that occurred on December 8, 2015. The filing concerns the termination of a material definitive agreement involving the company's wholly owned Israeli subsidiary, Pluristem Ltd.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual event rather than periodic financial performance.
Material Changes
On December 8, 2015, Pluristem received notice from United Therapeutics Corporation (United) terminating an exclusive license agreement originally signed on June 19, 2011. Key changes resulting from this termination include:
- Pluristem regains full rights to its PLacental eXpanded (PLX) cells specifically for the field of Pulmonary Arterial Hypertension (PAH).
- Pluristem regains ownership of all clinical data and regulatory submissions related to the PAH product.
- The exclusive worldwide license rights previously held by United for the development and commercialization of the PLX cell-based product for PAH are voided.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future strategy, or a discussion of risks beyond the immediate impact of the agreement termination. The termination was effective immediately upon notice.
Investor Verification Checklist
- Verify the specific terms of the termination clause regarding any potential financial penalties or payments owed to United Therapeutics.
- Confirm the status of the clinical data and regulatory submissions now returned to Pluristem.
- Assess Pluristem's immediate plans to re-license or internally develop the PLX product for PAH now that rights have been regained.
- Review the original 2011 agreement to understand the payment schedule that was interrupted by the termination.